RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and functionally contributes to increase tumor aggressiveness

ABSTRACT: Analyses of genes expression in estrogen receptor negative, RANK positive, breast cancer orthoxenografts after in vivo treatment (4 weeks) with RANKL , RANK-Fc or denosumab.

ORGANISM(S): Homo sapiens

PROVIDER: GSE185513 | GEO | 2023/01/19

REPOSITORIES: GEO